Our purpose was to study the safety, distribution, pharmacokinetics, immunogenicity, and tumor response of intraperitoneal 212Pb-TCMCtrastuzumab (TCMC is S-2-(4-isothiocyanatobenzyl)-1,4,7,10- tetraaza-1,4,7,10-tetra(2-carbamoylmethyl)cyclododecane) in patients with human epidermal growth factor receptor type 2 (HER-2)- expressing malignancy.
